Federal Register / Vol. 66, No. 83 / Monday, April 30, 2001 / Notices 21407

Institutes of Health, Department of

Health and Human Services, is

contemplating the grant of an exclusive

license to practice the inventions

embodied in U.S. Patent Application S/

N 08/533,895, filed on September 26,

1995, entitled ‘‘MHC Class II Restricted

Melanoma Antigens and Their Use in

Therapeutic Methods’’, to Therion

Biologics Corporation of Cambridge,

Massachusetts. The patent rights in

these inventions have been assigned to

the United States of America.

The prospective exclusive license

territory will be worldwide and the field

of use may be limited to recombinant

poxvirus-based vaccines for human

cancer immunotherapy, said poxviruses

encoding Class II-restricted melanoma

antigens, or modifications, derivatives,

or immunogenic peptides thereof, and

vaccination protocols comprising the

administration of one or more Class IIrestricted melanoma peptides in

addition to a recombinant poxvirusbased vaccine (for example, in a prime

and boost protocol), but specifically

excluding the use of these peptides in

any context other than a recombinant

poxvirus-based vaccination protocol.

DATES: Only written comments and/or

license applications which are received

by the National Institutes of Health on

or before June 29, 2001 will be

considered.

ADDRESSES: Requests for copies of the

patent application, inquiries, comments

and other materials relating to the

contemplated exclusive license should

be directed to: Elaine White, M.B.A.,

Technology Licensing Specialist, Office

of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville, MD.

20852–3804. Telephone: (301) 496–

7056, X282; Facsimile (301) 402–0220;

E-mail eg46t@nih.gov.

SUPPLEMENTARY INFORMATION: The

prospective exclusive license will be

royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless

within sixty (60) days from the date of

this published notice, the NIH receives

written evidence and argument that

establish that the grant of the license

would not be consistent with the

requirements of 35 U.S.C. 209 and 37

CFR 404.7.

Applications for a license in the field

of use filed in response to this notice

will be treated as objections to the grant

of the contemplated exclusive license.

Comments and objections submitted to

this notice will not be made available

for public inspection and, to the extent

permitted by law, will not be released

under the Freedom of Information Act,

5 U.S.C. 552.

Dated: April 23, 2001.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 01–10578 Filed 4–27–01; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: Human Papilloma Inhibition

by Antisense Oligonucleotides

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i), that the National

Institutes of Health (NIH), Department

of Health and Human Services, is

contemplating the grant of an exclusive

license to practice the invention

embodied in: Korean Patent Application

10–2000–7002392 entitled ‘‘Human

Papilloma Inhibition by Antisense

Oligonucleotides’’ filed on June 30,

2000, to Gyn-Gen Bio, Inc., having a

place of business in Seoul, Korea. The

patent rights in this invention have been

assigned to the United States of

America.

DATES: Only written comments and/or

application for a license which are

received by the NIH Office of

Technology Transfer on or before June

29, 2001 will be considered.

ADDRESSES: Requests for a copy of the

patent applications, inquiries,

comments and other materials relating

to the contemplated license should be

directed to: Peter Soukas, Office of

Technology Transfer, National Institutes

of Health, 6011 Executive Boulevard,

Suite 325, Rockville, MD 20852–3804;

Email: ps193c@nih.gov; Telephone:

(301) 496–7056, ext. 268; Facsimile:

(301) 402–0220.

SUPPLEMENTARY INFORMATION: The

present invention relates to the use of

antisense oligonucleotides to inhibit

Human Papilloma Virus (HPV). The

antisense oligonucleotides have a

phosphorothioate backbone structure

and sequences complimentary to

portions of the human papilloma virus

16 E6 gene. See the equivalent United

States patent number 6,084,090 and

Alvarez-Salas et al., ‘‘Growth inhibition

of cervical tumor cells by antisense

oligodeoxynucleotides directed to the

human papillomavirus type 16 E6

gene,’’ Antisense Nucleic Acid Drug Dev

1999 Oct;9(5):441–50 for further details.

The prospective exclusive license will

be royalty bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless,

within 60 days from the date of this

published Notice, NIH receives written

evidence and argument that establishes

that the grant of the license would not

be consistent with the requirements of

35 U.S.C. 209 and 37 CFR 404.7.

The field of use may be limited to

treatment and prevention of Human

Papilloma Virus infection with

antisense oligonucleotides. The licensed

territory is expected to be limited to

Korea, China, Malaysia and Thailand.

Properly filed competing applications

for a license filed in response to this

notice will be treated as objections to

the contemplated license. Comments

and objections submitted in response to

this notice will not be made available

for public inspection, and, to the extent

permitted by law, will not be released

under the Freedom of Information Act,

5 U.S.C. 552.

Dated: April 20, 2001.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer

[FR Doc. 01–10577 Filed 4–27–01; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: Identification of TRP–2 as a

New Human Tumor Antigen

Recognized by Cytotoxic T

Lymphocytes

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i), that the National

Institutes of Health, Department of

Health and Human Services, is

contemplating the grant of an exclusive

license to practice the inventions

embodied in U.S. Patent Applications S/

N 08/725,736, filed on October 4, 1996,

and now U.S. Patent 5,831,016 which

issued on November 3, 1998; S/N 09/

161,877 (DIV of 08/725,736), filed on

September 28, 1998, and now U.S.

Patent 6,132,980 which issued on

October 17, 2000; S/N 09/162,368 (DIV

of 08/725,736), filed on September 28,